Navigation Links
CareFusion to Resume Shipping Alaris(R) Infusion Products
Date:7/10/2009

SAN DIEGO, July 10 /PRNewswire/ -- CareFusion Corporation, the company that will become public from the planned spinoff of Cardinal Health's clinical and medical products businesses, today announced it will immediately resume customer implementations of its Alaris(R) PC units and PCA (Patient Controlled Analgesia) modules following a shipping hold announced in March.

The company is ready to resume shipments following 510(k) clearance from the Food and Drug Administration (FDA) for a software correction that will be implemented on new Alaris PC units.

"The 510(k) clearance for our software correction is another important milestone in our continued progress under the amended consent decree," said Dwight Winstead, chief operating officer of CareFusion. "We will continue to work closely with the FDA to fulfill all of our obligations under the amended consent decree and execute within our new quality system to manufacture products that are among the safest in the industry."

The 510(k) clearance follows FDA acceptance of the company's corrective action plan for field remediation of its infusion pumps that was announced on June 9. For Alaris PC units already with customers, CareFusion will begin implementing the software correction as part of this corrective action plan.

About CareFusion Corporation

CareFusion Corporation, a wholly owned subsidiary of Cardinal Health (NYSE: CAH), is expected to become a public company from the planned spinoff of Cardinal Health's clinical and medical products businesses. The global company serves the health care industry with products and services that help hospitals measurably improve the safety and quality of health care. CareFusion develops market-leading technologies including Alaris(R) IV pumps, Pyxis(R) automated dispensing and patient identification systems, AVEA and Pulmonetic Systems ventilation and respiratory products, ChloraPrep(R) and MedMined(TM) services for infection prevention, neurological monitoring and diagnostic products, V. Mueller(R) surgical instruments, and an extensive line of products that support interventional medicine.

CareFusion employs more than 15,000 people across its global operations and serves customers in 120 countries. The company has applied to have its shares of common stock listed on the New York Stock Exchange under the ticker symbol "CFN." More information may be found at www.carefusion.com.

Cautions Concerning Forward-Looking Statements

This news release contains forward-looking statements addressing the planned spinoff of Cardinal Health's clinical and medical products businesses as a separate company named CareFusion Corporation, which is dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual events (including the planned spinoff) and results to differ materially from those projected, anticipated or implied. These risks and uncertainties include uncertainties regarding the planned spinoff of CareFusion, including the timing and terms of any such spinoff and whether such spinoff will be completed as it is subject to a number of conditions. In addition, Cardinal Health and CareFusion are subject to additional risks and uncertainties described in CareFusion's Form 10, as amended, and Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports. Except to the extent required by applicable law, Cardinal Health and CareFusion undertake no obligation to update or revise any forward-looking statement.


'/>"/>
SOURCE CareFusion Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareFusion Corporation Files Form 10 Registration Statement
2. CareFusion Names Edward Borkowski as Chief Financial Officer
3. CareFusion Announces Board of Directors, Progress on Alaris Consent Decree
4. CareFusion Names Robert Friel to Board of Directors
5. CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety
6. CareFusion Files Amended Form 10 Registration Statement With SEC
7. CareFusion Corporation Launches International Jazz Festival Series
8. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
9. Douglas A. McClain, Jr. Resumes CFO Duties at Immunosyn
10. BioElectronics Corporations Commercial Resumes on Bloomberg Television
11. China Shenghuo to Resume Trading on NYSE Alternext US LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home ... as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade to ... consumers look for home care close to home, and by having city-specific pages, NuevaCare ...
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... TaskMate Go. Core benefits and advantages built into the home office sit stand ... look and feel. Ability to gain the benefits embedded in the TaskMate Go ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
(Date:2/24/2017)... ... ... With millions of Americans and people worldwide struggling with ... aware of our options and are empowered with strength and information throughout the ... newest edition of "Vision and Hearing" in USA Today, that will educate readers ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
Breaking Medicine Technology: